🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK2269557

Found 12 matching trials

An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

PHASE2

The purpose of this study is to evaluate the efficacy of GSK2269557 adminis...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-03-31

Trial ID

NCT02294734

Treatments Being Tested

GSK2269557 Placebo

A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

PHASE2

This study is a multi-centre, randomised, double-blind, placebo-controlled ...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-10-01

Trial ID

NCT02567708

Treatments Being Tested

GSK2269557 DPI Placebo DPI

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

Nemiralisib is being developed as an anti-inflammatory drug for the treatme...

Status

Terminated

Location

GSK Investigational Site

Start Date

2017-11-28

Trial ID

NCT03345407

Treatments Being Tested

Placebo ELLIPTA Nemiralisib ELLIPTA 50 µg Nemiralisib ELLIPTA 100 µg Nemiralisib ELLIPTA 250 µg Nemiralisib ELLIPTA 500 µg Nemiralisib ELLIPTA 750 µg Albuterol (Salbutamol) MDI or nebules Standard of care therapy

Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects

PHASE1

GSK2269557 is being developed as an anti-inflammatory and anti-infective ag...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-06-15

Trial ID

NCT03189589

Treatments Being Tested

GSK2269557 500 µg GSK2269557 750 µg

Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

PHASE2

This is an open-label study conducted to investigate safety, pharmacokineti...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-07-22

Trial ID

NCT02593539

Treatments Being Tested

Nemiralisib

Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557

PHASE1

The study will comprise three Parts: Part A will consist of two cohorts of...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-07-24

Trial ID

NCT01462617

Treatments Being Tested

GSK2269557 GSK2269557 matching placebo

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

PHASE1

GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3-Kina...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10

Trial ID

NCT02972905

Treatments Being Tested

GSK2269557 ELLIPTA DPI Placebo ELLIPTA DPI

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients

PHASE2

This is a randomised, double-blind, placebo controlled, parallel group stud...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-07-31

Trial ID

NCT02130635

Treatments Being Tested

GSK2269557 100 MCG GSK2269557 500 MCG PLACEBO

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects

PHASE1

GSK2269557 is potent and highly selective inhaled phosphoinositides 3-kinas...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-01-09

Trial ID

NCT01762878

Treatments Being Tested

GSK2269557 Placebo

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

PHASE1

GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3-Kina...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-03-14

Trial ID

NCT02691325

Treatments Being Tested

GSK2269557 ELLIPTA DPI Placebo ELLIPTA DPI Activated charcoal

Previous Next